Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Up – What’s Next?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) gapped up prior to trading on Monday . The stock had previously closed at $39.41, but opened at $41.01. Tarsus Pharmaceuticals shares last traded at $39.39, with a volume of 73,455 shares.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on TARS. Oppenheimer reissued an “outperform” rating and set a $63.00 price target (up from $61.00) on shares of Tarsus Pharmaceuticals in a research note on Friday, August 9th. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Tarsus Pharmaceuticals currently has an average rating of “Buy” and an average price target of $51.60.

Tarsus Pharmaceuticals Stock Down 0.6 %

The company has a debt-to-equity ratio of 0.28, a current ratio of 7.03 and a quick ratio of 6.99. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -8.79 and a beta of 1.07. The firm has a 50 day simple moving average of $32.16 and a two-hundred day simple moving average of $31.21.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.10. Tarsus Pharmaceuticals had a negative return on equity of 63.99% and a negative net margin of 180.00%. The firm had revenue of $40.81 million during the quarter, compared to analysts’ expectations of $31.30 million. During the same period in the previous year, the firm earned ($1.17) earnings per share. As a group, sell-side analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.71 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Jennison Associates LLC acquired a new position in shares of Tarsus Pharmaceuticals during the 1st quarter worth about $48,380,000. Quantbot Technologies LP acquired a new position in Tarsus Pharmaceuticals during the first quarter worth $410,000. Swiss National Bank lifted its stake in Tarsus Pharmaceuticals by 1.4% in the first quarter. Swiss National Bank now owns 42,433 shares of the company’s stock valued at $1,542,000 after acquiring an additional 600 shares during the last quarter. Sei Investments Co. grew its position in shares of Tarsus Pharmaceuticals by 128.2% in the 1st quarter. Sei Investments Co. now owns 32,804 shares of the company’s stock valued at $1,192,000 after acquiring an additional 18,426 shares during the period. Finally, Thoroughbred Financial Services LLC acquired a new position in shares of Tarsus Pharmaceuticals during the 1st quarter worth about $762,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.